Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 72.51

From 52W high−44.16%

Volume6.11M

Market capCNY 31.05B

P/E (TTM)200.3x

P/S (TTM)2.5x

Div yield0.22%

Key dataSep 18, 2026

Open

CNY 72.51

From 52W high

−44.16%

Volume

6.11M

Market cap

CNY 31.05B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

27.1x

P/E (TTM)

200.3x

RSI (14)

40.7

MomentumView details →

1D Return

−4.26%

YTD Return

−22.74%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

200.3x

EV/EBITDA

27.1x

EV/Sales

2.7x

P/S (TTM)

2.5x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

79.62%

Net Margin

−0.36%

EBITDA Margin

9.92%

ROE (TTM)

−0.19%

ROA (TTM)

−0.14%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

−12.14%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−1.46%

EPS CAGR 3Y

−66.41%

EBITDA YoY

—

MomentumView details →

1D Return

−4.26%

YTD Return

−22.74%

1Y Return

−42.90%

RSI (14)

40.7

vs 50D SMA

−7.27%

vs 200D SMA

−14.82%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

3.52x

Quick Ratio

2.10x

Div Yield

0.22%

Div Rate

CNY 0.16

Div Growth 1Y

−93.85%

EarningsView details →

EPS (Actual)

CNY 0.50

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

11.67B

Net Income (TTM)

−41.99M

Op. CF (TTM)

1.33B

Next earningsOct 26, 2026 →

Latest newsMore news →

Changchun High-tech's subsidiary Jinsai Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of GenSci161 injection, a self-developed biologic drug for connective tissue disease-associated interstitial lung disease.20d ago

Changchun High-Tech announced it will not distribute cash dividends, bonus shares, or convert capital reserve to share capital for H1 2026.31d ago

Similar companies

展芯股份301707.SZ 欧陆通300870.SZ 鹏辉能源300438.SZ 新希望000876.SZ 九安医疗002432.SZ 汇绿生态001267.SZ Find similar companies →

Latest newsMore news →

Changchun High-tech's subsidiary Jinsai Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of GenSci161 injection, a self-developed biologic drug for connective tissue disease-associated interstitial lung disease.20d ago Changchun High-Tech announced it will not distribute cash dividends, bonus shares, or convert capital reserve to share capital for H1 2026.31d ago Changchun High-Tech announced its H1 2026 results: revenue of 5.543 billion yuan, down 16.06% year-on-year; net profit attributable to shareholders of 475 million yuan, down 51.64% year-on-year; non-GAAP net profit of 496 million yuan, down 52.02% year-on-year.31d ago